Research Perspectives:
Targeting GITR in cancer immunotherapy – there is no perfect knowledge
PDF | Full Text | How to cite | Press Release
Metrics: PDF 1073 views | Full Text 2105 views | ?
Abstract
Diwakar Davar1,2 and Roberta Zappasodi3,4
1 Hillman Cancer Center, University of Pittsburgh Medical Center (UPMC), Pittsburgh, PA 15232, USA
2 University of Pittsburgh, Pittsburgh, PA 15232, USA
3 Division of Hematology and Medical Oncology, Department of Medicine, Weill Cornell Medical College, NY 10065, USA
4 Immunology and Microbial Pathogenesis Program, Weill Cornell Graduate School of Medical Sciences, NY 10065, USA
Correspondence to:
Diwakar Davar, | email: | [email protected] |
Keywords: cancer; immunotherapy; programmed death-1 (PD-1); cytotoxic T-lymphocyte Antigen-4 (CTLA-4); glucocorticoid-induced TNFR-related protein (GITR)
Received: April 19, 2023 Accepted: June 05, 2023 Published: June 19, 2023
ABSTRACT
Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily (TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells. Given its potential to promote T effector function and impede Treg immune suppression, GITR is an attractive target for cancer immunotherapy. Preclinically, GITR agonists have demonstrated potent anti-tumor efficacy singly and in combination with a variety of agents, including PD-1 blockade. Multiple GITR agonists have been advanced into the clinic, although the experience with these agents has been disappointing. Recent mechanistic insights into the roles of antibody structure, valency, and Fc functionality in mediating anti-tumor efficacy may explain some of the apparent inconsistency or discordance between preclinical data and observed clinical efficacy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28461